Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie som utvärderar Atezolizumab, med eller utan Bevacizumab, hos patienter med icke-operabelt hepatocellulärt karcinom och Child-Pugh B7 och B8 cirros (Kirros)

6 november 2026 uppdaterad av: Genentech, Inc.

En fas II, öppen, multikohort, multicenterstudie på patienter med icke-operabelt hepatocellulärt karcinom och Child-Pugh B7 och B8 cirros

The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.

Studieöversikt

Status

Aktiv, inte rekryterande

Detaljerad beskrivning

This is a Phase II, open-label, multicohort, multicenter study in participants with unresectable, locally advanced, or metastatic HCC who have Child-pugh B7 or B8 liver cirrhosis and have received no prior systemic therapy in this treatment setting. The study is designed to non-comparatively evaluate the safety of atezolizumab plus bevacizumab (Cohort A) or atezolizumab monotherapy (Cohort B) in this population.

Studietyp

Interventionell

Inskrivning (Faktisk)

30

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Arizona
      • Tucson, Arizona, Förenta staterna, 85724
        • University of Arizona Cancer Center
    • California
      • La Jolla, California, Förenta staterna, 92093
        • UC San Diego Moores Cancer Center
      • Los Angeles, California, Förenta staterna, 90089-5601
        • University of Southern California-Keck School of Medicine -1975 Zonal Ave
      • Newport Beach, California, Förenta staterna, 92663
        • University of Southern California
      • Orange, California, Förenta staterna, 92868
        • University of California Irvine Medical Center
      • Pasadena, California, Förenta staterna, 91105-2561
        • California Liver Research Institute
      • Sacramento, California, Förenta staterna, 95817
        • University of California Davis Medical Center
      • Stanford, California, Förenta staterna, 94305
        • Stanford Health Care
      • Torrance, California, Förenta staterna, 90502-2006
        • Harbor UCLA Medical Center
      • West Hollywood, California, Förenta staterna, 90048-2422
        • Cedars Sinai Comprehensive Transplant Center
    • Connecticut
      • Hartford, Connecticut, Förenta staterna, 06106
        • Hartford Healthcare Cancer Institute at Hartford Hospital
    • District of Columbia
      • Washington D.C., District of Columbia, Förenta staterna, 20037
        • George Washington University- Medical Faculty Associates
      • Washington D.C., District of Columbia, Förenta staterna, 20422-0001
        • Washington DC VA Medical Center
    • Florida
      • Orlando, Florida, Förenta staterna, 32806
        • Orlando Health Inc.
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60611-2908
        • Northwestern University
      • Chicago, Illinois, Förenta staterna, 60612-4795
        • University of Illinois Health Outpatient Care Center
      • Chicago, Illinois, Förenta staterna, 60637-1426
        • The Duchossois Center for Advanced Medicine
    • Kentucky
      • Lexington, Kentucky, Förenta staterna, 40536-7001
        • University of Kentucky - Markey Cancer Center
    • Louisiana
      • Baton Rouge, Louisiana, Förenta staterna, 70805
        • LSU Health Baton Rouge
      • Baton Rouge, Louisiana, Förenta staterna, 70808-4300
        • Our Lady of the Lake Cancer Institute
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02215
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Förenta staterna, 02111
        • Tufts Medical Center
    • Michigan
      • Detroit, Michigan, Förenta staterna, 48201
        • Barbara Ann Karmanos Cancer Institute
      • Detroit, Michigan, Förenta staterna, 48202
        • Henry Ford Health System
    • Missouri
      • Kansas City, Missouri, Förenta staterna, 64111
        • Saint Luke?s Hospital of Kansas City
    • New Jersey
      • New Brunswick, New Jersey, Förenta staterna, 08901
        • Rutgers Cancer Institute of New Jersey
      • Newark, New Jersey, Förenta staterna, 07103
        • Rutgers Cancer Institute of New Jersey at University Hospital
    • New York
      • Mineola, New York, Förenta staterna, 11501-4064
        • NYU Langone Hospital - Long Island
      • New York, New York, Förenta staterna, 10029
        • Icahn School of Medicine at Mount Sinai
      • The Bronx, New York, Förenta staterna, 10467
        • Montefiore Medical Center
      • The Bronx, New York, Förenta staterna, 10468-3904
        • James J Peters Veterans Administration Medical Center - NAVREF
    • North Carolina
      • Charlotte, North Carolina, Förenta staterna, 28204
        • Levine Cancer Institute
    • Ohio
      • Dayton, Ohio, Förenta staterna, 45428-9000
        • Dayton VA Medical Center - NAVREF - PPDS
    • Oklahoma
      • Oklahoma City, Oklahoma, Förenta staterna, 73104-5020
        • The University of Oklahoma Health Sciences Center
    • Oregon
      • Hillsboro, Oregon, Förenta staterna, 97124-5806
        • Kaiser Permanente Westside Medical Center
      • Portland, Oregon, Förenta staterna, 97239-3011
        • OHSU Knight Cancer Institute Hematology Oncology
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19107
        • Jefferson Health Honickman Center
      • Pittsburgh, Pennsylvania, Förenta staterna, 15240
        • Veterans Affairs Pittsburgh Healthcare System - NAVREF - PPDS
    • Tennessee
      • Germantown, Tennessee, Förenta staterna, 38138-1762
        • The West Clinic (East Campus)
      • Nashville, Tennessee, Förenta staterna, 37208-2918
        • Nashville General Hospital at Meharry
    • Texas
      • Dallas, Texas, Förenta staterna, 75390-0001
        • University of Texas Southwestern Medical Center
      • Dallas, Texas, Förenta staterna, 75246-2008
        • Texas Oncology (Worth) - USOR
      • Dallas, Texas, Förenta staterna, 75203-1260
        • Liver Institute at Methodist Dallas
      • Dallas, Texas, Förenta staterna, 75235
        • Moody Outpatient Center ? Parkland Health
      • Denison, Texas, Förenta staterna, 75020-0084
        • Texas Oncology - Denison Cancer Center
      • Houston, Texas, Förenta staterna, 77025-1669
        • Kelsey Research Foundation
      • Houston, Texas, Förenta staterna, 77030-4211
        • Michael E Debakey VA Medical Center - NAVREF - PPDS
    • Utah
      • Murray, Utah, Förenta staterna, 84107-5741
        • Intermountain Healthcare
      • St. George, Utah, Förenta staterna, 84790
        • Intermountain Cancer Center
    • Virginia
      • Falls Church, Virginia, Förenta staterna, 22042
        • Inova Schar Cancer Institute
      • Richmond, Virginia, Förenta staterna, 23226-1925
        • Bon Secours St. Mary's Hospital
      • Richmond, Virginia, Förenta staterna, 23298-5028
        • VCU Medical Center North Hospital
    • Washington
      • Seattle, Washington, Förenta staterna, 98101
        • Virginia Mason Medical Center
      • Rio Piedras, Puerto Rico, 00935
        • Pan American Center for Oncology Trials, LLC

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

General Inclusion Criteria:

  • Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants
  • Disease that is not amenable to curative surgical and/or locoregional therapies
  • No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and/or unresectable HCC
  • Measurable disease (at least one untreated target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 7 days prior to initiation of study treatment
  • Child-pugh B7 or B8 cirrhosis at screening and within 7 days prior to study treatment
  • Adequate hematologic and end-organ function
  • Life expectancy of at least 12 weeks
  • Female participants of childbearing potential must be willing to avoid pregnancy and egg donation
  • Absolute neutrophil count (ANC) ≥1.0 x 10^9 per liter (/L) (≥1000 per microliter [/μL]) without granulocyte colony-stimulating factor support
  • Platelet count ≥ 50 × 109/L (50,000/μL) without transfusion
  • Hemoglobin (Hb) ≥ 80 grams per liter (g/L) (8 grams per deciliter [g/dL])
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × upper limit of normal (ULN)
  • Serum bilirubin ≤ 3 × ULN
  • Creatinine clearance ≥ 50 milliliters per minute (mL/min) (calculated using the Cockcroft-gault formula)
  • Serum albumin ≥ 20 g/L (2.0 g/dL) without transfusion in the prior 3 months
  • International normalized ratio (INR) ≤2.3

General Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure
  • Treatment with systemic immunostimulatory agents
  • Treatment with systemic immunosuppressive medication
  • Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment
  • Inadequately controlled hypertension
  • Active or history of autoimmune disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Participants who have a known concurrent malignancy that is progressing or requires active treatment, who have not completely recovered from treatment, or who have a significant malignancy history that, in the opinion of the investigator, should preclude participation
  • Participants on preventative hormonal therapies (i.e., tamoxifen and other hormonal inhibitors) are not excluded
  • Known fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC
  • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
  • Prior allogeneic stem cell or solid organ transplantation
  • Actively listed for liver transplantation
  • Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)
  • Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding
  • A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment
  • Grade ≥3 hemorrhage or bleeding event within 6 months prior to initiation of study treatment
  • Hepatic encephalopathy is allowed if no active symptoms or stable within 3 months of study treatment
  • History, planned, or recommended placement of transjugular intrahepatic portosystemic shunt (TIPS) is excluded from Cohort A only. TIPS is acceptable in Cohort B
  • Diagnostic paracentesis is allowed. Therapeutic paracentesis: one large volume paracentesis prior to enrollment with diuretic controlled ascites is allowed.
  • Participants with ascites controlled on diuretics are allowed
  • History of spontaneous bacterial peritonitis within last 12 months

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Cohort A: Atezolizumab+Bevacizumab

Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator.

Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.

Andra namn:
  • Tecentriq; RO5541267

Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) by IV infusion on Day 1 of each 21-day cycle.

Andra namn:
  • Avastin; RO4876646
Experimentell: Cohort B: Atezolizumab

Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator.

Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.

Andra namn:
  • Tecentriq; RO5541267

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Percentage of Participants With Adverse Events (AEs)
Tidsram: Baseline through the end of the study (up to approximately 36 months)

An AE is any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Severity is determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0) in Cohorts A and B.

Baseline through the end of the study (up to approximately 36 months)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Studierektor: Clinical Trials, Hoffmann-La Roche

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

15 juli 2024

Primärt slutförande (Beräknad)

30 juli 2027

Avslutad studie (Beräknad)

30 december 2027

Studieregistreringsdatum

Först inskickad

18 oktober 2023

Först inskickad som uppfyllde QC-kriterierna

18 oktober 2023

Första postat (Faktisk)

24 oktober 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

9 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera